Facile Synthesis of Dendritic Mesoporous Silica Nanoparticles for Co-loading of Doxorubicin and Hemoglobin

doi:10.15541/jim20180076

Abstract

Abstract:

Tumor hypoxia is a ubiquitous factor to cause the therapeutic resistance of drug or other treatments. To solve this problem, a facile biophase stratification approach was developed to fabricate dendritic mesoporous silica nanoparticles (DMSNs) with small particle size of 65 nm, high dispersity and excellent biostability through simply controlling the oil-water interfacial reaction. The resultant DMSNs were characterized by various techniques such as scanning electron microscope (SEM), transmission electron microscope (TEM), dynamic light scattering (DLS), and N₂ adsorption-desorption analysis, etc. It is verified that DMSNs possess two types of pore size (2.7 nm and 5.4-6.8 nm), high specific surface (654.52 m²/g) and pore volume (1.26 cm³/g), which are capable to co-load DOX and Hb, simultaneously. Moreover, the mesopore size in the dendritic mesoporous layer could be tuned by changing the amounts of triethanolamine (TEA). The testing results from drug release, flow cytometry histograms, confocal laser scanning microscopy, and cell cytotoxicity demonstrate that DMSNs possess high efficiency of drug release (75.6%), durable releasing period (48 h) and significantly enhanced cell lethality (IC₅₀= 20.6 μg/mL). These data demonstrate that such kind of dentritic mesoporous silica naoparticles has great potentials in drug delivery and tumor chemotherapy.

Key words: tumor hypoxia, small size, dendritic mesoporous silica nanoparticles, drug delivery

CLC Number:

TQ174

PAN Shan, LI Yong-Sheng, SHI Jian-Lin. Facile Synthesis of Dendritic Mesoporous Silica Nanoparticles for Co-loading of Doxorubicin and Hemoglobin[J]. Journal of Inorganic Materials, 2018, 33(10): 1097-1102.

Figures/Tables 8

Fig. 1 Schematic illustration for the preparation of DMSNs

Fig. 2 TEM images of MSNs (a, b), DMSNs-0 (c, d), DMSNs-0.3 (e, f), and DMSNs-0.6 (g, h) at different magnification

Fig. 3 DLS size distribution curves of MSNs, DMSNs-0, DMSNs- 0.3, and DMSNs-0.6

Fig. 4 N2 adsorption-desorption isotherms (a) and corresponding BJH pore size distributions (b) of MSNs, DMSNs-0, DMSNs-0.3, and DMSNs-0.6

Table 1 Pore structural parameters of the synthesized MSNs, DMSNs-0, DMSNs-0.3, and DMSNs-0.6

Sample	Specific surface area/(m²·g^-1)	Pore diameter/nm	Pore volume/ (cm³·g^-1)
MSNs	525.81	2.7	1.02
DMSNs-0	342.86	1.7	0.70
DMSNs-0.3	469.16	2.7 & 5.4	0.83
DMSNs-0.6	654.52	2.7 & 6.8	1.26

Fig. 5 Biostability testing of DMSNs (a) and cumulative drug release of Hb/DOX@DMSN in PBS with pH=7.4 and pH=5.4 (b)

Fig. 6 Flow cytometry histograms (a) and CLSM images (b) of SMMC-7721 cells after being incubated with Hb/DOX@DMSN for 1 h, 4 h, 8 h, and 24 h

Fig. 7 Cell viability of SMMC-7721 cells incubated with Hb/DOX@DMSNs, DOX@DMSNs and free DOX with different concentrations of DOX for 24 h

References 23

[1]	ZHU W W, DONG Z L, FU T T, et al. Modulation of hypoxia in solid tumor microenvironment with MnO2 nanoparticles to enhance photodynamic therapy. Advanced Functional Materials, 2016, 26(30): 5490-5498.
[2]	CHEN Q, FENG L Z, LIU J J, et al. Intelligent albumin-MnO2 nanoparticles as pH-/H2O2-responsive dissociable nanocarriers to modulate tumor hypoxia for effective combination therapy. Advanced Materials, 2016, 28(33): 7129-7136.
[3]	SONG X J, FENG L Z, LIANG C, et al. Ultrasound triggered tumor oxygenation with oxygen-shuttle nanoperfluorocarbon to overcome hypoxia-associated resistance in cancer therapies. Nano Letters, 2016, 16(10): 6145-6153.
[4]	LUO Z Y, ZHENG M B, ZHAO P F, et al. Self-monitoring artificial red cells with sufficient oxygen supply for enhanced photodynamic therapy. Scientific Reports, 2016, 6(1): 1-11.
[5]	TIAN H, LUO Z, LIU L,et al. Cancer cell membrane-biomimetic oxygen nanocarrier for breaking hypoxia-induced chemoresistance. Advanced Functional Materials, 2017, 27(38): 1703197-1-7.
[6]	CHENG Y, CHENG H, JIANG C, et al. Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy. Nature Communications, 2015, 6(1): 8785-8793.
[7]	BU H X, XU X, CHEN J M, et al. Synthesis of a hemoglobin- conjugated triblock copolymer for oxygen carrying and specific recognition of cancer cells. RSC Advances, 2017, 7(76): 48166-48175.
[8]	LIU Y H, LIU R T.Spectroscope and molecular model identify the behavior of doxorubicin-SPION binding to bovine hemoglobin.International Journal of Biological Macromolecules, 2015, 79: 564-569.
[9]	HUANG M X, LIU L, WANG S G, et al. Dendritic mesoporous silica nanospheres synthesized by a novel dual-templating micelle system for the preparation of functional nanomaterials. Langmuir, 2017, 33(2): 519-526.
[10]	SHEN D K, YANG J P, LI X M, et al. Biphase stratification approach to three-dimensional dendritic biodegradable mesoporous silica nanospheres. Nano Letters, 2014, 14(2): 923-932.
[11]	KNEŽEVIĆ N Ž, DURAND J O. Large pore mesoporous silica nanomaterials for application in delivery of biomolecules.Nanoscale, 2015, 7(6): 2199-2209.
[12]	SHIN H S, HWANG Y K, HUH S.Facile preparation of ultra-large pore mesoporous silica nanoparticles and their application to the encapsulation of large guest molecules.ACS Applied Materials & Interfaces, 2014, 6(3): 1740-1746.
[13]	XU C, YU M H, NOONAN O, et al. Core-cone structured monodispersed mesoporous silica nanoparticles with ultra-large cavity for protein delivery. Small, 2015, 11(44): 5949-5955.
[14]	DU X, SHI B, LIANG J, et al. Developing functionalized dendrimer- like silica nanoparticles with hierarchical pores as advanced delivery nanocarriers. Advanced Materials, 2013, 25(41): 5981-5985.
[15]	OSAKI F, KANAMORI T, SANDO S, et al. A quantum dot conjugated sugar ball and its cellular uptake. on the size effects of endocytosis in the subviral region. Journal of the American Chemical Society, 2004, 126(21): 6520-6521.
[16]	LU F, WU S H, HUNG Y, et al. Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles. Small, 2009, 5(12): 1408-1413.
[17]	PAN L M, LIU J N, HE Q J, et al. MSN-mediated sequential vascular- to-cell nuclear-targeted drug delivery for efficient tumor regression. Advanced Materials, 2014, 26(39): 6742-6748.
[18]	PAN L M, LIU J N, HE Q J, et al. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles. Biomaterials, 2013, 34(11): 2719-2730.
[19]	PAN L M, HE Q J, LIU J N, et al. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. Journal of the American Chemical Society, 2012, 134(13): 5722-5725.
[20]	LI N, NIU D C, JIANG Y, et al. Morphology evolution and spatially selective functionalization of hierarchically porous silica nanospheres for improved multidrug delivery. Chemistry of Materials, 2017, 29(24): 10377-10385.
[21]	CHEN Y, CHEN H, GUO L, et al. Hollow/rattle-type mesoporous nanostructures by a structural difference-based selective etching strategy. ACS Nano, 2009, 4(1): 529-539.
[22]	TU J, BOYLE A L, FRIEDRICH H, et al. Mesoporous silica nanoparticles with large pores for the encapsulation and release of proteins. ACS Applied Materials & Interfaces, 2016, 8(47): 32211-32219.
[23]	SINGH R K, KIM T H, MAHAPATRA C, et al. Preparation of self-activated fluorescence mesoporous silica hollow nanoellipsoids for theranostics. Langmuir, 2015, 31(41): 11344-11352.